Human adult bone marrow-derived stem cells decrease severity of lipopolysaccharide-induced acute respiratory distress...

Area of Science:

• Pulmonary Medicine
• Regenerative Medicine
• Critical Care

Background:

• Acute respiratory distress syndrome (ARDS) is a primary cause of respiratory failure in critically ill patients, often stemming from sepsis or pneumonia.
• Current treatments for ARDS are limited to protective ventilation and fluid management.
• Novel therapeutic strategies are urgently required to improve outcomes for ARDS patients.

Purpose of the Study:

• To investigate the efficacy of adult stem cell therapy in a pre-clinical model of ARDS.
• To evaluate the impact of intrabronchial stem cell delivery on physiological parameters in endotoxin-induced ARDS.

Main Methods:

• The study utilized an ovine model, inducing ARDS via intravenous endotoxin infusion in 14 sheep.
• Six of these sheep received varying doses of adult stem cells administered via intrabronchial delivery.
• Control animals received saline solution.

Main Results:

• Endotoxin infusion led to a significant decrease in oxygenation, characteristic of moderate-to-severe ARDS.
• Sheep treated with 40 million adult stem cells demonstrated a return to baseline oxygen levels within two hours.
• Significant improvements were observed in carbon dioxide clearance, pulmonary vascular pressures, lung edema, and inflammation markers.

Conclusions:

• Intrabronchial administration of adult non-hematopoietic stem cells effectively mitigated the effects of endotoxin in the ovine ARDS model.
• Stem cell therapy accelerated the recovery of oxygenation and carbon dioxide removal while reducing inflammation.
• Adult stem cells represent a promising alternative therapeutic approach for ARDS.